Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Clin Transplant. 2018 Jun 29;32(8):e13302. doi: 10.1111/ctr.13302

Figure 1.

Figure 1

Sampling scheme for mutually exclusive regimens. Metformin-based includes any metformin use, regardless of comedications. Insulin-based includes insulin and any other drug, except metformin. Glitazone-based includes glitazones and any other drug, except metformin and insulin. Sulfonylurea-based includes sulfonylurea and any other drug, except metformin, insulin or glitazones. “Other” diabetes treatment regimens include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1)- receptor agonists, meglitinides, alpha-glucosidase inhibitors, amylin analog and sodium-glucose co-transporter 2 (SGLT2) inhibitors.